Resveratrol improves endothelial cell markers impaired by plasma incubation from women who subsequently develop preeclampsia

Autor(es)

Caldeira-Dias, Mayara ^[1] ; Montenegro, Marcelo F. ^[2] ; Bettiol, Heloisa ^[3] ; Barbieri, Marco Antonio ^[3] ; Cardoso, Viviane C. ^[3] ; Cavalli, Ricardo C. ^[4] ; Sandrim, Valeria C. ^[1]

Afiliação do(s) autor(es)

^[1] Univ Estadual Paulista UNESP, Inst Biosci Botucatu, Dept Pharmacol, BR-18680000 Botucatu, SP - Brazil

^[2] Karolinska Inst Biomed, Dept Physiol & Pharmacol FYFA, S-17177 Stockholm - Sweden

^[3] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Pediat, BR-14049900 Ribeirao Preto, SP - Brazil

^[4] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Gynecol & Obstet, BR-14049900 Ribeirao Preto, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: HYPERTENSION RESEARCH; v. 42, n. 8, p. 1166-1174, AUG 2019.
• Citações Web of Science: 0

Resumo

In this study, we demonstrated that plasma collected from women who subsequently developed preeclampsia caused increased heme oxygenase-1 (HO-1) production and decreased levels of nitric oxide (NO) markers in endothelial cells (HUVECs). Conversely, no changes in HO-1 or NO markers were found when HUVECs were treated with plasma from women who remained healthy throughout pregnancy. These alterations in HO-1 and NO markers were prevented by cotreatment with the polyphenol resveratrol, which also improved GSH levels. In addition, we evaluated changes induced by plasma incubation in the expression of genes and their related pathways associated with antioxidant defenses, such as Nrf2, ARE activity, and GSR. Collectively, our findings suggest that even before the appearance of clinical symptoms of preeclampsia, plasma from affected women is able to induce modifications in endothelial cells with respect to HO-1 production and NO markers. We believe that this in vitro strategy may offer an attractive alternative to the exploitation of candidate markers or screening molecules, such as resveratrol, for the prevention and management of preeclampsia. (AU)

• Processo FAPESP: 08/53593-0 - Fatores etiológicos da prematuridade e conseqüências dos fatores perinatais na saúde da criança: coortes de nascimentos em duas cidades brasileiras
• Beneficiário: Marco Antonio Barbieri
• Linha de fomento: Auxílio à Pesquisa - Temático
• Processo FAPESP: 15/20461-8 - Papel do Nrf2 e HO-1 em pré-eclâmpsia: estudo de polimorfismos genéticos, fatores circulantes e ensaios in vitro
• Beneficiário: Valeria Cristina Sandrim
• Linha de fomento: Auxílio à Pesquisa - Regular